혈액 악성 종양 검사 시장 : 세계 및 지역별 분석 - 제품별, 플랫폼별, 질환별, 최종사용자별, 지역별 - 분석과 예측(2024-2033년)

Global Hematologic Malignancies Testing Market Industry Overview

The global hematologic malignancies testing market was valued at $3,546.3 million in 2023 and is expected to reach $13,509.5 million by 2033, growing at a CAGR of 14.09% during the forecast period 2024-2033. The hematologic malignancies testing market focuses on diagnostic tools and technologies for detecting and monitoring blood cancers such as leukemia, lymphoma, and myeloma. With the growing incidence of these cancers and advancements in diagnostic methods, the market is rapidly expanding. Key technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry. These tools are crucial for accurate diagnosis, prognosis, and treatment planning.

The growth of the hematologic malignancies testing market is driven by several factors, such as the rising burden of hematological cancer, growing research publications, and clinical trials in hematologic malignancies testing, leading to increased demand for hematologic malignancies tests and products. Additionally, increased funding and community support for early detection and treatment create a demand for hematological malignancy testing kits and services, and continuous advancements in hematologic malignancy have led to the development of more effective and innovative tests and kits. Moreover, the expanding availability of these supplements through various distribution channels, including online platforms and retail stores, has further facilitated market expansion and accessibility to consumers worldwide.

Market Introduction

The hematological malignancies testing market focuses on diagnostic tools and technologies used to identify and monitor cancers of the blood, including leukemia, lymphoma, and myeloma. This market is growing significantly, driven by the rising incidence of these cancers, technological advancements in diagnostics, and a focus on early detection and personalized medicine. The rising prevalence of hematologic malignancies globally highlights substantial growth potential in the healthcare sector. GLOBOCAN projects a 56.37% increase in these cancers by 2050 compared to 2022. As these diseases become more widespread across various regions, there is expected to be a growing need for advanced diagnostic tools, effective therapeutic interventions, and comprehensive supportive care services to meet the increasing healthcare demands.

The growing emphasis on personalized oncology and targeted therapies for hematological cancer treatment has fuelled demand for companion diagnostics tests on hematologic malignancies testing. Facilitation of its adoption in clinical practices by government approvals and reimbursement policies has paved the way for their integration into standard oncology care. As awareness about early cancer detection and its non-invasive diagnostic method continues to rise, the hematologic malignancies testing market is poised for further expansion and diversification in the coming years.

Industrial Impact

The growth of the hematologic malignancies testing market has not only provided relief to individuals having cancer symptoms but has also had a notable industrial impact. Manufacturers and suppliers of these products have witnessed increased demand, leading to expanded production capacities and job creation within the industry.

Market Segmentation:

Segmentation 1: by Product

• Kits
• Services

Services Segment to Dominate the Hematologic Malignancies Testing Market (by Product)

The services segment is expected to dominate the hematologic malignancies testing market by product. This is primarily due to the complexity of tests and the advanced technology required in performing the hematologic malignancies testing. The service providers not only perform the tests but also handle data analysis.

Segmentation 2: by Platform

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Platforms

Polymerase Chain Reaction (PCR) Segment to Dominate the Hematologic Malignancies Testing Market (by Platform)

The polymerase chain reaction (PCR) segment is anticipated to dominate the hematologic malignancies testing market by platform. This predominance results from its rapid turnaround times and high sensitivity and specificity, which are essential for detecting and quantifying specific genetic changes linked to various hematologic cancers.

Segmentation 3: by Disease

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myeloproliferative Neoplasms
• Myelodysplastic Syndrome

Leukemia Segment to Dominate the Hematologic Malignancies Testing Market (by Diseases)

The leukemia segment is expected to dominate the hematologic malignancies testing market based on diseases. This predominance results from the high prevalence and incidence of leukemia, which elevates the demand for diagnostic testing. The complexity of leukemia, with its various subtypes requiring specific diagnostic methods, further intensifies the need for comprehensive testing.

Segmentation 4: by End User

• Specialty Clinics and Hospitals
• Diagnostic Laboratories
• Reference Laboratories

Specialty Clinics and Hospitals Segment to Dominate the Hematologic Malignancies Testing Market (by End User)

The specialty clinics and hospitals segment of the hematologic malignancies testing market by end user is expected to lead the market. This leadership stems from their integrated patient care models that ensure timely and coordinated diagnosis and treatment, which are critical for hematologic malignancies. These facilities feature advanced infrastructure to support sophisticated diagnostic tools and employ specialized personnel essential for interpreting complex test results.

Segmentation 5: by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Denmark
  • Rest-of-Europe
• Asia-Pacific
  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Singapore
  • Rest-of-Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest-of-Latin America
• Middle East and Africa
  • K.S.A.
  • U.A.E.
  • South Africa
  • Rest-of-Middle East and Africa

The North America region is positioned to hold a significant share of the global market for several compelling reasons. North America's growth has been driven by high rates of hematologic malignancies in the U.S. and Canada. Europe and Asia-Pacific are expected to see substantial growth, with China showing strong performance and increased adoption in Japan and India. Strategic partnerships in Latin America and other regions are tackling infrastructure challenges, thereby creating opportunities for manufacturers and service providers worldwide.

Recent Developments in the Hematologic Malignancies Testing Market

• In May 2024, Bruker Corporation acquired ELITech Group with an expectation of generating revenue of $100 million by ELITech Group from the remainder of 2024.
• In April 2024, QIAGEN N.V. announced the launch of the QIAseq Targeted RNA-seq Panel for T-cell receptors, emphasizing their critical role in the adaptive immune system's function of recognizing and eliminating abnormal cells, including cancer cells.
• In February 2024, Precipio, Inc. announced the signing of a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio's HemeScreen portfolio of molecular assays to its customer base, primarily comprising acute healthcare systems (hospital networks), reference laboratories, and physician-owned laboratories.
• In January 2024, Illumina, Inc. announced it signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration marks the first step in developing Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to enhance understanding of disease persistence or recurrence after clinical intervention.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

Rising Incidence of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Leukemia Facilitating the Demand for Hematologic Malignancy Testing Kits and Services: The increasing prevalence of hematologic malignancies globally highlights significant growth potential in the healthcare sector. GLOBOCAN projects a 56.37% rise in these cancers by 2050 compared to 2022. As these diseases become more common across various regions, there will be a critical need for advanced diagnostic tools, effective therapeutic interventions, and comprehensive supportive care services to meet the growing healthcare demands.

Market Challenges:

Challenges in Integrating NGS into Clinical Practice for Hematologic Malignancies: Integrating next-generation sequencing (NGS) into clinical diagnostics for hematologic malignancies encounters significant challenges, hindering market growth. Despite its potential to transform disease classification, risk assessment, and treatment decisions, the complexity of interpreting and applying NGS-derived molecular genetic data remains a major obstacle. The phenotypic and genetic diversity of acute and chronic myeloid malignancies requires advanced expertise and sophisticated bioinformatic tools to differentiate clinically relevant driver mutations from incidental passenger mutations.

Market Opportunities:

Leveraging AI for Enhanced Diagnostics in the Hematologic Malignancies Testing Market: Integrating artificial intelligence (AI) into the diagnosis of hematologic malignancies offers a significant business opportunity in the global hematologic malignancies testing market. Researchers at the Ohio State University Comprehensive Cancer Center have demonstrated AI's potential to accurately differentiate between two rare blood cancers, prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET). This distinction is crucial for determining appropriate treatment and enrolling patients in clinical trials, a task that traditional diagnostic methods find challenging.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global hematologic malignancies testing market has been segmented based on various categories, such as products, platforms, diseases, end users, and regions.

Growth/Marketing Strategy: Partnerships, alliances, funding, and business expansions together accounted for the maximum number of key developments of the total developments in the 'Hematologic Malignancies Testing Market' between January 2020 and May 2024.

Competitive Strategy: The global hematologic malignancies testing market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the hematologic malignancies testing market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of hematologic malignancies testing.
• The market contribution of hematologic malignancy testing anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
• Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023.
• The market has been mapped based on the available hematologic malignancies testing products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in hematologic malignancies testing, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of the report's segmentation and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of the different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players of the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Based on product, the hematologic malignancies testing market service segment players leading the market captured around 58.36% of the market's presence as of 2023. Kits, on the other hand, accounted for approximately 41.64% of the market presence in 2023, respectively.

Some prominent names established in this market are:

• Abbott Laboratories
• Adaptive Biotechnologies
• ARUP Laboratories
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• ICON plc
• Illumina, Inc.
• Invitae Corporation
• Invivoscribe Inc.
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories
• OHSU's Knight Diagnostic Laboratories
• QIAGEN N.V.
• Quest Diagnostics
• Sysmex Corporation
• Tempus Labs, Inc
• Bio-Techne
• DiaSorin S.p.A
• Foundation Medicine, Inc.
• Thermo Fisher Scientific, Inc.
• ELITech Group
• Vela Diagnostics
• Amoy Diagnostics Co., Ltd.
• Integrated DNA Technologies, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Global Hematologic Malignancies Testing Market: Market Overview

• 1.1 Introduction
• 1.2 Types of Hematologic Malignancies Diagnostic Tests
• 1.3 Market Footprint and Growth Potential

2 Global Hematologic Malignancies Testing Market: Industry Analysis

• 2.1 Key Trends: Current and Future Impact Assessment
  • 2.1.1 Growing Utilization of Next-Generation Sequencing and Artificial Intelligence in Hematologic Malignancies Testing
  • 2.1.2 Increasing Partnerships, Alliances, and Business Expansions among Key Players
• 2.2 Regulatory Framework
  • 2.2.1 Regulatory Framework in the U.S.
  • 2.2.2 Regulatory Framework in Europe
  • 2.2.3 Regulatory Framework in Asia-Pacific
    • 2.2.3.1 Japan
    • 2.2.3.2 China
• 2.3 COVID-19's Impact on Cancer Diagnostic Market
• 2.4 Supply Chain Analysis
  • 2.4.1 Key Entities in Supply Chain
• 2.5 Pricing Analysis
• 2.6 Comparative Analysis of Hematologic Malignancies Test by Different Parameters

3 Global Hematologic Malignancies Testing Market: Market Dynamics

• 3.1 Impact Analysis
• 3.2 Market Drivers
  • 3.2.1 Rising Incidence of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Leukemia Facilitating the Demand for Hematologic Malignancy Testing Kits and Services
  • 3.2.2 Increased Funding and Community Support for Early Detection and Treatment to Create a Demand for Hematologic Malignancy Testing Kits and Services
  • 3.2.3 Continuous Advancements in Hematologic Malignancy Testing
• 3.3 Market Restraints
  • 3.3.1 Challenges in Integrating NGS into Clinical Practice for Hematologic Malignancies
  • 3.3.2 Unfavorable Reimbursement Scenario
• 3.4 Market Opportunities
  • 3.4.1 Strategic Partnerships to Enhance Diagnostic Capabilities in Emerging Markets
  • 3.4.2 Leveraging AI for Enhanced Diagnostics in the Hematologic Malignancies Testing Market

4 Global Hematologic Malignancies Testing Market (by Product)

• 4.1 Product Summary
• 4.2 By Product
  • 4.2.1 Kits
    • 4.2.1.1 Gene Panels
    • 4.2.1.2 Molecular Clonality Testing
    • 4.2.1.3 Translocation Testing
    • 4.2.1.4 Mutation Testing
    • 4.2.1.5 Minimal Residual Testing
  • 4.2.2 Services

5 Global Hematologic Malignancies Testing Market (by Platform)

• 5.1 Platform Summary
• 5.2 By Platform
  • 5.2.1 Next-Generation Sequencing
    • 5.2.1.1 Polymerase Chain Reaction (PCR)
  • 5.2.2 Fluorescence In-Situ Hybridization
  • 5.2.3 Immunohistochemistry
  • 5.2.4 Flow Cytometry
  • 5.2.5 Other Platforms
    • 5.2.5.1 Cytogenetic Testing
    • 5.2.5.2 Microarray

6 Global Hematologic Malignancies Testing Market (by Diseases)

• 6.1 Diseases Summary
• 6.2 By Diseases
  • 6.2.1 Leukemia
  • 6.2.2 Lymphoma
  • 6.2.3 Multiple Myeloma
  • 6.2.4 Myeloproliferative Neoplasms
  • 6.2.5 Myelodysplastic Syndromes

7 Global Hematologic Malignancies Testing Market (by End User)

• 7.1 End User Summary
• 7.2 By End User
  • 7.2.1 Specialty Clinics and Hospitals
  • 7.2.2 Diagnostic Laboratories
  • 7.2.3 Reference Laboratories

8 Global Hematologic Malignancies Testing Market (By Region)

• 8.1 Regional Summary
• 8.2 Drivers and Restraints
• 8.3 North America
  • 8.3.1 Regional Overview
  • 8.3.2 Driving Factors for Market Growth
  • 8.3.3 Factors Challenging the Market
  • 8.3.4 U.S.
  • 8.3.5 Canada
• 8.4 Europe
  • 8.4.1 Regional Overview
  • 8.4.2 Driving Factors for Market Growth
  • 8.4.3 Factors Challenging the Market
  • 8.4.4 Germany
  • 8.4.5 U.K.
  • 8.4.6 Spain
  • 8.4.7 Italy
  • 8.4.8 France
  • 8.4.9 Denmark
  • 8.4.10 Rest-of-Europe
• 8.5 Asia-Pacific
  • 8.5.1 Regional Overview
  • 8.5.2 Driving Factors for Market Growth
  • 8.5.3 Factors Challenging the Market
  • 8.5.4 China
  • 8.5.5 Japan
  • 8.5.6 India
  • 8.5.7 Australia
  • 8.5.8 South Korea
  • 8.5.9 Singapore
  • 8.5.10 Rest-of-Asia-Pacific
• 8.6 Latin America
  • 8.6.1 Regional Overview
  • 8.6.2 Driving Factors for Market Growth
  • 8.6.3 Factors Challenging the Market
  • 8.6.4 Brazil
  • 8.6.5 Mexico
  • 8.6.6 Rest-of-Latin America
• 8.7 Middle East and Africa
  • 8.7.1 Regional Overview
  • 8.7.2 Driving Factors for Market Growth
  • 8.7.3 Factors Challenging the Market
  • 8.7.4 K.S.A.
  • 8.7.5 U.A.E.
  • 8.7.6 South Africa
  • 8.7.7 Rest-of-Middle East and Africa

9 Global Hematologic Malignancies Testing Market - Competitive Benchmarking and Company Profiles

• 9.1 Key Strategies and Development
  • 9.1.1 Partnerships, Alliances, and Business Expansions
  • 9.1.2 Regulatory and Legal Activities
  • 9.1.3 New Offerings
  • 9.1.4 Mergers and Acquisitions
• 9.2 Market Share
• 9.3 Company Profiles
  • 9.3.1 Abbott Laboratories
    • 9.3.1.1 Overview
    • 9.3.1.2 Top Products
    • 9.3.1.3 Top Competitors
    • 9.3.1.4 Top Customers
    • 9.3.1.5 Key Personnel
    • 9.3.1.6 Corporate Strategies
    • 9.3.1.7 Analyst View
  • 9.3.2 Adaptive Biotechnologies
    • 9.3.2.1 Overview
    • 9.3.2.2 Top Products
    • 9.3.2.3 Top Competitors
    • 9.3.2.4 Top Customers
    • 9.3.2.5 Key Personnel
    • 9.3.2.6 Corporate Strategies
    • 9.3.2.7 Analyst View
  • 9.3.3 ARUP Laboratories
    • 9.3.3.1 Overview
    • 9.3.3.2 Top Products
    • 9.3.3.3 Top Competitors
    • 9.3.3.4 Top Customers
    • 9.3.3.5 Key Personnel
    • 9.3.3.6 Analyst View
  • 9.3.4 Bio-Rad Laboratories, Inc.
    • 9.3.4.1 Overview
    • 9.3.4.2 Top Products
    • 9.3.4.3 Top Competitors
    • 9.3.4.4 Top Customers
    • 9.3.4.5 Key Personnel
    • 9.3.4.6 Analyst View
  • 9.3.5 F. Hoffmann-La Roche Ltd.
    • 9.3.5.1 Overview
    • 9.3.5.2 Top Products
    • 9.3.5.3 Top Competitors
    • 9.3.5.4 Key Customers
    • 9.3.5.5 Key Personnel
    • 9.3.5.6 Corporate Strategies
    • 9.3.5.7 Analyst View
  • 9.3.6 ICON plc
    • 9.3.6.1 Overview
    • 9.3.6.2 Top Products
    • 9.3.6.3 Top Competitors
    • 9.3.6.4 Top Customers
    • 9.3.6.5 Key Personnel
    • 9.3.6.6 Analyst View
  • 9.3.7 Illumina, Inc.
    • 9.3.7.1 Overview
    • 9.3.7.2 Top Products
    • 9.3.7.3 Top Competitors
    • 9.3.7.4 Top Competitors
    • 9.3.7.5 Key Personnel
    • 9.3.7.6 Corporate Strategies
    • 9.3.7.7 Analyst View
  • 9.3.8 Invitae Corporation
    • 9.3.8.1 Overview
    • 9.3.8.2 Top Products
    • 9.3.8.3 Top Competitors
    • 9.3.8.4 Top Customers
    • 9.3.8.5 Key Personnel
    • 9.3.8.6 Corporate Strategies
    • 9.3.8.7 Analyst View
  • 9.3.9 Invivoscribe Inc.
    • 9.3.9.1 Overview
    • 9.3.9.2 Top Products
    • 9.3.9.3 Top Competitors
    • 9.3.9.4 Top Customers
    • 9.3.9.5 Key Personnel
    • 9.3.9.6 Analyst View
  • 9.3.10 Laboratory Corporation of America Holdings
    • 9.3.10.1 Overview
    • 9.3.10.2 Top Products
    • 9.3.10.3 Top Competitors
    • 9.3.10.4 Top Customers
    • 9.3.10.5 Key Personnel
    • 9.3.10.6 Corporate Strategies
    • 9.3.10.7 Analyst View
  • 9.3.11 NeoGenomics Laboratories
    • 9.3.11.1 Overview
    • 9.3.11.2 Top Products
    • 9.3.11.3 Top Competitors
    • 9.3.11.4 Top Customers
    • 9.3.11.5 Key Personnel
    • 9.3.11.6 Analyst View
  • 9.3.12 OHSU's Knight Diagnostic Laboratories
    • 9.3.12.1 Overview
    • 9.3.12.2 Top Products
    • 9.3.12.3 Top Competitors
    • 9.3.12.4 Top Customers
    • 9.3.12.5 Key Personnel
    • 9.3.12.6 Analyst View
  • 9.3.13 QIAGEN N.V.
    • 9.3.13.1 Overview
    • 9.3.13.2 Top Products
    • 9.3.13.3 Top Competitors
    • 9.3.13.4 Top Customers
    • 9.3.13.5 Key Personnel
    • 9.3.13.6 Corporate Strategies
    • 9.3.13.7 Analyst View
  • 9.3.14 Quest Diagnostics
    • 9.3.14.1 Overview
    • 9.3.14.2 Top Products
    • 9.3.14.3 Top Competitors
    • 9.3.14.4 Top Customers
    • 9.3.14.5 Key Personnel
    • 9.3.14.6 Corporate Strategies
    • 9.3.14.7 Analyst View
  • 9.3.15 Sysmex Corporation
    • 9.3.15.1 Overview
    • 9.3.15.2 Top Products
    • 9.3.15.3 Top Competitors
    • 9.3.15.4 Top Customers
    • 9.3.15.5 Key Personnel
    • 9.3.15.6 Analyst View
  • 9.3.16 Tempus Labs, Inc
    • 9.3.16.1 Overview
    • 9.3.16.2 Top Products
    • 9.3.16.3 Top Competitors
    • 9.3.16.4 Top Customers
    • 9.3.16.5 Key Personnel
    • 9.3.16.6 Analyst View
  • 9.3.17 Bio-Techne
    • 9.3.17.1 Overview
    • 9.3.17.2 Top Products
    • 9.3.17.3 Top Competitors
    • 9.3.17.4 Top Customers
    • 9.3.17.5 Key Personnel
    • 9.3.17.6 Analyst View
  • 9.3.18 DiaSorin S.p.A
    • 9.3.18.1 Overview
    • 9.3.18.2 Top Products
    • 9.3.18.3 Top Competitors
    • 9.3.18.4 Top Customers
    • 9.3.18.5 Key Personnel
    • 9.3.18.6 Corporate Strategies
    • 9.3.18.7 Analyst View
  • 9.3.19 Foundation Medicine, Inc.
    • 9.3.19.1 Overview
    • 9.3.19.2 Top Products
    • 9.3.19.3 Top Competitors
    • 9.3.19.4 Top Customers
    • 9.3.19.5 Key Personnel
    • 9.3.19.6 Analyst View
  • 9.3.20 Thermo Fisher Scientific, Inc.
    • 9.3.20.1 Overview
    • 9.3.20.2 Top Products
    • 9.3.20.3 Top Competitors
    • 9.3.20.4 Top Customers
    • 9.3.20.5 Key Personnel
    • 9.3.20.6 Corporate Strategies
    • 9.3.20.7 Analyst View
  • 9.3.21 ELITech Group
    • 9.3.21.1 Overview
    • 9.3.21.2 Top Products
    • 9.3.21.3 Top Competitors
    • 9.3.21.4 Top Customers
    • 9.3.21.5 Analyst View
  • 9.3.22 Vela Diagnostics
    • 9.3.22.1 Overview
    • 9.3.22.2 Top Products
    • 9.3.22.3 Top Competitors
    • 9.3.22.4 Top Customers
    • 9.3.22.5 Key Personnel
    • 9.3.22.6 Analyst View
  • 9.3.23 Amoy Diagnostics Co., Ltd.
    • 9.3.23.1 Overview
    • 9.3.23.2 Top Products
    • 9.3.23.3 Top Competitors
    • 9.3.23.4 Top Customers
    • 9.3.23.5 Key Personnel
    • 9.3.23.6 Analyst View
  • 9.3.24 Integrated DNA Technologies, Inc.
    • 9.3.24.1 Overview
    • 9.3.24.2 Top Products
    • 9.3.24.3 Top Competitors
    • 9.3.24.4 Top Customers
    • 9.3.24.5 Key Personnel
    • 9.3.24.6 Corporate Strategies
    • 9.3.24.7 Analyst View

10 Research Methodology

• 10.1 Data Sources
  • 10.1.1 Primary Data Sources
  • 10.1.2 Secondary Data Sources
  • 10.1.3 Data Triangulation